Literature DB >> 26065476

Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.

Paul A Beavis1,2, Clare Y Slaney1,2, Michael H Kershaw1,2,3,4, Paul J Neeson1,2, Phillip K Darcy1,2,3,4.   

Abstract

Strategies aimed at stimulating the immune system against cancer have signaled a new era for designing new effective therapies for patients. Recent breakthroughs in adoptive cellular therapy and in using checkpoint inhibitors for some patients have renewed much enthusiasm in this field. However, it has become apparent that tumors can use a multitude of inhibitory networks to effectively reduce antitumor immunity. This review discusses our current knowledge of these immune suppressive mechanisms used by tumors and describes potential new strategies that may counteract this problem resulting in significantly increasing therapeutic outcomes of adoptive immunotherapy in a higher proportion of patients.

Entities:  

Keywords:  T cells; adoptive cellular therapy; checkpoint blockade; chemotherapy; chimeric antigen receptor; cytokine; genetic modification; immunosuppression; radiotherapy; tumor

Mesh:

Year:  2015        PMID: 26065476     DOI: 10.2217/imt.15.16

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  6 in total

1.  Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Authors:  Paul A Beavis; Melissa A Henderson; Lauren Giuffrida; Jane K Mills; Kevin Sek; Ryan S Cross; Alexander J Davenport; Liza B John; Sherly Mardiana; Clare Y Slaney; Ricky W Johnstone; Joseph A Trapani; John Stagg; Sherene Loi; Lev Kats; David Gyorki; Michael H Kershaw; Phillip K Darcy
Journal:  J Clin Invest       Date:  2017-02-06       Impact factor: 14.808

2.  Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.

Authors:  Mohanad H Nada; Hong Wang; Grefachew Workalemahu; Yoshimasa Tanaka; Craig T Morita
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

Review 3.  Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.

Authors:  Mei Zhang; Julian A Kim; Alex Yee-Chen Huang
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

4.  A novel ferroptosis-related long noncoding RNA signature for relapse free survival prediction in patients with breast cancer.

Authors:  Yuzhi Wang; Yunfei Xu; Yi Zhang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

5.  Efficacy and safety of cord blood-derived dendritic cells plus cytokine-induced killer cells combined with chemotherapy in the treatment of patients with advanced gastric cancer: a randomized Phase II study.

Authors:  Ying Mu; Wei-Hua Wang; Jia-Ping Xie; Ying-Xin Zhang; Ya-Pei Yang; Chang-Hui Zhou
Journal:  Onco Targets Ther       Date:  2016-07-25       Impact factor: 4.147

6.  Targeting CD73 in the tumor microenvironment with MEDI9447.

Authors:  Carl M Hay; Erin Sult; Qihui Huang; Kathy Mulgrew; Stacy R Fuhrmann; Kelly A McGlinchey; Scott A Hammond; Raymond Rothstein; Jonathan Rios-Doria; Edmund Poon; Nick Holoweckyj; Nicholas M Durham; Ching Ching Leow; Gundo Diedrich; Melissa Damschroder; Ronald Herbst; Robert E Hollingsworth; Kris F Sachsenmeier
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.